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Abstract
Background: Egg donor agencies are increasingly being used as part of IVF in the US, but are essentially unregulated,
posing critical ethical and policy questions concerning how providers view and use them, and what the implications
might be.
Methods: Thirty-seven in-depth interviews of approximately 1 h were conducted – with 27 IVF providers and 10 patients.
Results: Clinicians vary in their views and interactions concerning egg donor agencies, ranging widely in whether
and how often they use agencies. Agencies may offer egg recipients increased choices, but raise ethical and other
concerns regarding respect for donors as individuals (e.g., adequacy of informed consent), potential harms, justice
(e.g., concerns about possible eugenics – by encouraging and facilitating selection and marketing of facts for offspring),
and donors constituting a vulnerable group. The quality of agencies appears to vary considerably, from acceptable to
problematic. Agencies’ medical and psychological screenings of donors can range, and be minimal. Not all agencies
adequately track donors’ prior numbers of donations, or share the relevant records with clinics. Clinics may find that
potential donors have genetic mutations and medical problems about which they were unaware. Yet agencies and
clinics do not provide care for such donors, generating stress. Dissemination of donors’ personal data can potentially
threaten confidentiality. Questions emerge of whether increased monitoring/oversight of agencies may be beneficial.
Conclusions: These data, the first to examine providers’ views and interactions regarding egg donor agencies, suggest
wide variations in quality and use of agencies, and have critical implications for practice, policy, education and research.
Given the potential limitations of the current model of self-regulation of agencies, the present data suggest needs to
consider stronger professional guidelines or possible governmental regulations to establish, require and enforce higher
standards for agencies to follow, regarding advertising to potential donors and recipients, arranging for appropriate
informed consent concerning risks and benefits involved, and for quality control. Appropriate informed consent should
be obtained from potential egg donors, including the fact that they may learn about mutations or medical problems
about which they were unaware, but for which they will not receive treatment as part of this process. Enhancing
understanding among the public-at-large about what egg donation entails may also be helpful.
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Background
Assisted reproductive technology (ART) has posed a
range of critical ethical concerns, but perhaps none
more dramatically and controversially, as buying and
selling human eggs. The US is one of the only countries
in the world that permits compensation for oocytes. All
countries in the European Union ban such compensa-
tion (except for reimbursement of minimal basic
expenses such as for time, inconvenience and transpor-
tation [1]. Consequently, hundreds of egg donor agencies
have been established in the US, but remain essentially
unregulated, posing ethical questions [2–5].
Approximately 10 % of the population in all countries
are infertile and many women delay childbirth in order
first to pursue careers, often leading to fertility prob-
lems. Single individuals, as well as gay and lesbian
couples, are also now using IVF (in vitro fertilization) to
have children. Approximately 10.5 % of ART treatments
in the United States (US) use eggs from donors [6].
These issues are also of broader significance outside the
US, since egg donors may be paid in other countries
(e.g., India) [7], and many foreigners travel to the US for
infertility treatment, and purchase eggs.
In the US, IVF clinics are essentially self-regulated,
with guidelines published by the American Society for
Reproductive Medicine (ASRM) addressing compensat-
ing, recruiting and communicating risks/benefits to egg
donors [8]. ASRM states, for instance, that “it would be
prudent to limit donors to those who are 21 or older
and have the emotional maturity to make such deci-
sions” [9]. In 2007, the organization recommended
that donors do not undergo the procedure more than
six times in their lifetime (Practice Committee of the
ASRM and Practice Committee of the Society of
Assisted Reproductive Technologies [SART] [10] –
partly since donation carries medical risks, including
1.2 % risk of ovarian hyperstimulation syndrome [11],
and questions remain as to whether fertility drugs
that donors must take may increase risks of uterine
or other cancers [12].
Compensation should not vary according to the
planned use of the oocytes retrieved, the number or
outcome of prior donation cycles, or the donor’s
ethnic or other personal characteristics; and total
payments to donors in excess of $5,000 require
justification and sums above $10,000 are not
appropriate.
But in 2013, Lindsey Kamakahi sued ASRM, alleging
that these guidelines for payments constituted price
fixing; and in 2016, ASRM settled the lawsuit [13–15],
eliminating recommendations concerning caps on com-
pensation or egg donation.
Yet while the amounts of compensation have been ex-
amined, other critical questions concerning how egg
sellers interface and interact with ART providers have
received far less attention. Agencies exist as third-party
companies outside of professional medicine and are not
regulated by state or the federal government [16] or sub-
ject to professional codes of conduct, and are even less
influenced by a model of self-regulation. The only effort
made to regulate agencies regarding these issues has
consisted of ASRM allowing agencies to agree voluntar-
ily to that organization’s guidelines in exchange for a list-
ing on ASRM’s website as a professional endorsement.
Yet this initiative has only partially led participating
agencies to comply fully with these guidelines. Research
suggests that most agencies do not follow these recom-
mendations. Agencies advertise widely in college news-
papers, and advertisements of prices for eggs in college
newspapers increase with the average SAT scores of the
school [5], raising concerns about eugenics-related
searches for “the best genes.” Among a study of agency
and clinic ads on Craigslist, 81 % of agency and 96 % of
clinic ads were non-compliant with ARSM guidelines,
including 85 % of those agencies and clinics that were
SART-registered [17]. Most egg donor agencies fail to
comply with ASRM’s guidelines that bar varying
compensation based on a donor’s traits, with 58.8 %
explicitly stating that they pay more for certain traits,
and an additional 17.6 % stating that certain traits are
“preferred” or “in demand.” The most commonly-
mentioned compensated trait was prior donation suc-
cess. While ASRM recommended not using donors
under 21 years of age, 45.8 % of agency websites sought
younger donors.
Though the American Medical Association guidelines
require that health websites present risks alongside com-
pensation, 98 % of the agency websites presented com-
pensation amounts, but 74 % did not mention
psychological and/or emotional risks, none mentioned
possible cancer risks, 47.1 % failed to mention short-
term risks, and 88.7 % did not mention possible risk to
future fertility. Among websites of IVF clinics and egg
donor agencies, 92.2 and 58.8 %, respectively, were
SART or ASRM approved, but 39.7 % of these were still
inconsistent with ASRM guidelines, with 25.6 %
explicitly paying more for certain traits and 14.1 % stat-
ing that certain traits were “preferred” or “in demand”.
Agencies were more likely than clinics to offer a
range of fees rather than a fixed amount (78.4 % vs.
13.7 %), to specify “preferred” traits (76.5 % vs
21.6 %), and to fail to acknowledge a possible cancer
risk (100 % vs. 92.2 %).
Agency websites often seek to influence potential
donors to see donation as natural and fulfilling; and
attempt to influence potential donors through both
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monetary and non-monetary benefits that may inappro-
priately focus donors and recipients on personal gain, ra-
ther than on relevant medical considerations. These
companies portray egg donors in familiar, reassuring
ways to assuage recipients’ fears about using reproduct-
ive material from strangers, including in donor profiles a
range of donor personality characteristics, physical or
artistic talents and intellectual abilities, passion and
sense of purpose in life, and general temperament or
demeanor, and promulgate misunderstandings, making
emotional appeals that can distract recipients from
appropriate assessments of risks and benefits, and rais-
ing issues related to commodification, commercialization
over professionalism, and eugenics. Indeed, Ameling
interviewed staff at two egg donation agencies, who
described encouraging donors to present “properly fem-
inine profiles” [18]. These messages may, however,
inappropriately inject emotional cues into donors’ and
recipients’ decisions.
Yet strikingly, these past findings do not appear to have
altered professional or other guidelines or policies. In
part, understanding and awareness of these issues may
remain relatively limited. Hence, additional data and in-
sights concerning these companies, that affect attitudes
and practices of countless individuals, can potentially
help enhance comprehension of, and attention to, these
businesses among providers in various fields, patients,
policymakers, and the public more broadly.
In particular, the past data raise crucial questions that
have not yet been explored concerning how ART pro-
viders themselves in fact view and interact with agencies
as ethical issues arise. Providers may play central roles
as gatekeepers concerning egg recipients’ use of agency
donors. Hence, clinicians’ perspectives and experiences
concerning agencies are critical. But no studies have ex-
amined how ART clinicians themselves see and interface
with these businesses. These domains are especially crit-
ical at the present time since the settlement of the Kama-
kahi case, eliminating caps on amounts of compensation,
as a result of which many more women may now seek to
sell their eggs, and to do so through agencies. Thus, as
part of a study on views of ART providers and patients to-
ward several key aspects of IVF, issues concerning egg
donor agencies were examined as well.
Methods
In brief, as summarized on Table 1, and described more
fully elsewhere as well [19], 37 in-depth semi-structured
telephone interviews of approximately 1 h each were
conducted in the US with 27 ART providers – 17 physi-
cians and 10 other providers (7 mental health providers,
2 nurses, and 1 other) – and 10 patients. One physician
and three other providers were also themselves patients.
Interviews (for sample questions, see Additional file 1)
explored participants’ views and decisions regarding
ethical issues concerning egg donation and other key
aspects of ART, and were systematically analyzed to
obtain detailed descriptions of these issues. Since the
participants were from throughout the US, interviews
were conducted by telephone. The Columbia University
Department of Psychiatry Institutional Review Board
approved use of an information sheet about the study
that was sent to all interviewees, who then provided ver-
bal consent, which was documented by the researcher.
Since no prior studies have been published examining
IVF providers' attitudes and practices concerning egg
donor agencies, qualitative methods were chosen be-
cause these can best elicit the full range and typologies
of attitudes, interactions and practices involved, and can
inform subsequent quantitative studies. Qualitative
methods have been used successfully to reveal critical
aspects of patient attitudes and practices concerning
views of other topics related to IVF – e.g., patients’
decisions concerning disclosures of donor oocytes [20].
From a theoretical standpoint, Geertz has advocated
studying aspects of individuals’ lives, decisions, and
social situations not by imposing theoretical structures,
but by trying to understand the individuals’ own experi-
ences, drawing on their own words and perspectives to
obtain a “thick description” [21]. The methods for the
present study adapted elements from “Grounded The-
ory” [22] and were thus informed by techniques of “con-
stant comparison,” with data from different contexts
compared for similarities and differences, to see if they
suggest hypotheses. This technique generates new ana-
lytic categories and questions, and checks them for rea-
sonableness. These methods have been used in several
other studies on key aspects of health behavior and
doctor-patient relationships and communications in gen-
etics and other areas [23–27]. During the ongoing
process of interviewing, the Principal Investigator (PI)
constantly considered the ways participants resemble or
Table 1 Characteristics of Sample
Male Female Total
Physicians 14 3 17
Physicians who are also patients 0 1 1
Type of Practice
University affiliated 5 1 6
Private Practice 9 2 11
Other ART providers (e.g., mental health
providers, nurses)
1 9 10
Other providers who are also patients 0 3 3
Patients 1 9 10
Total 16 21 37
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differ from each other, and the social, cultural, and med-
ical contexts and factors that contribute to differences.
Grounded Theory also involves both deductive and
inductive thinking, building inductively from the data to
an understanding of themes and patterns within the
data, and deductively, drawing on frameworks from
prior research and theories.
Participants
Patients and providers were recruited through listservs,
emails, and word-of-mouth. Providers were also re-
cruited through national ASRM meetings (e.g., PGD and
mental health provider interest group meetings). The PI
approached these meeting attendees to ascertain
whether they might be interested in participating in an
interview study, and if so, the PI subsequently emailed
them information about it. Most of those asked agreed
to participate, and did so. A mental health listserv was
also used, which is received by approximately 60 mem-
bers (not all of whom are active), of whom 15
responded, and the first 8 respondents were then inter-
viewed. Additional interviews were conducted as back-
ground, for informational purposes, with 8 physicians, 9
mental health providers and 14 patients; and informed,
but were not included in the final formal data analysis.
Interviews for the formal data analyses were conducted
with each group until “saturation” was reached (i.e., “the
point at which no new information or themes are ob-
served in the data” [28]). Interviewees were from across
the US. Providers described interactions with multiple
patients they had treated, and colleagues; and patients
often described interactions with multiple providers and
other patients.
Instruments
The semi-structured interview questionnaire was drafted
drawing on prior literature, and explored patients’ and
providers’ views, experiences and decisions concerning
multiple aspects of ART, including use of egg donor
agencies (See Appendix for sample questions).
Data analysis
Transcriptions and initial analyses of interviews occurred
during the period in which the interviews were being con-
ducted, enhancing validity, and helped shape subsequent
interviews. Once the full set of interviews was completed,
subsequent analyses were conducted in two phases, pri-
marily by trained research assistants (RAs) and the PI. In
phase I, they independently examined a subset of inter-
views to assess factors that shaped participants’ experi-
ences, identifying categories of recurrent themes and
issues that were subsequently given codes. The PI and
RAs read each interview, systematically coding blocks of
text to assign “core” codes or categories (e.g., views of use
of egg donor agencies, or interactions with them). While
reading the interviews, a topic name (or code) was
inserted beside each excerpt of the interview to indicate
the themes being discussed. The PI and RAs then worked
together to reconcile these independently developed cod-
ing schemes into a single scheme. Next, a coding manual
was prepared, defining each code and examining areas of
disagreement until reaching consensus. New themes that
did not fit into the original coding framework were
discussed, and modifications made in the manual when
deemed appropriate.
In phase II of the analysis, the PI and RAs independ-
ently content-analyzed the data to identify the principal
subcategories, and ranges of variation within each of the
core codes. They reconciled the sub-themes identified
by each coder into a single set of “secondary” codes and
an elaborated set of core codes. These codes assess sub-
categories and other situational and social factors. Such
subcategories included, for instance, views of egg donor
agencies as satisfactory or as problematic; and the
quality of screenings of donors by agencies.
Codes and sub-codes were then used in analysis of all
of the interviews. To ensure coding reliability, the PI
and an RA analyzed all interviews. Where necessary,
multiple codes were used. Similarities and differences
were assessed between participants, examining categor-
ies that emerged, ranges of variation within categories,
and variables that may be involved. Areas of disagree-
ment were examined through closer analysis until con-
sensus was reached. Regularly for consistency and
accuracy in ratings was checked regularly by comparing
earlier and later coded excerpts.
Text from the interviews is presented below to allow
readers to appreciate the richness of the data obtained.
Results
Overall, as outlined in Fig. 1 and described more fully
below, egg donor agencies appear to be increasing and
changing; but clinicians vary in how they view, and
whether and how often they use, these companies –
from rarely to often. Agencies pose critical ethical
concerns regarding informed consent, potential harms,
justice (related to possible eugenics), and donors consti-
tuting a vulnerable group. Providers perceived variations
in the quality of agencies. Medical and psychological
screenings of donors can range, and be minimal or lack-
ing. Agencies may not adequately track how many times a
woman has previously donated, and/or may list a donor as
available when she is not. Clinics may find that a donor
has medical issues about which she was unaware, causing
her stress. The dissemination of personal data about
donors can pose potential confidentiality problems. Ques-
tions arise of whether increased monitoring or oversight
of agencies may be beneficial.
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Increasing use of agencies
As the demand for donor eggs has risen, agencies may be
increasing, evolving, and affecting clinics’ practices. Due to
agencies, patients often have more choices and information
about donors than before. Providers have frequently altered
their recruitment of donors and use of agencies and many
clinics are increasingly working with these companies
Until recently, donors were anonymous. The clinics
chose the donors. But market forces have changed
things. The egg donor agencies are really taking over.
[Other provider #5]
Clinical practice has changed, increasing the use of
agencies, due not to altered regulations, but to market
forces, particularly the growth of agencies, giving
prospective parents more choices. Agencies have made
more information about prospective donors available,
potentially affecting clinics’ practices as well.
Clinics used to not show adult pictures of donors. But
now, prospective parents can see photos, and a lot of
patients want to. With these agencies, there are more
patients than before. [Other provider #5]
Many clinics may thus use agencies in order to give
patients more of a choice of potential donors – often
through websites.
When patients wanted to do donor egg, some clinics
would find the egg donor, and introduce that egg
donor, on paper, to the patient, and the patient would
have to either take her or leave her. A lot of people
want more say about who their donor is. They may
leave that clinic, and come to a program where they
can go to a donor agency, look at tons of profiles, and
pick someone who really seems right for them. [Other
provider-patient #10]
Clinics vary in how much and in what ways they work
with egg donor agencies. Many providers prefer to use
only donors they know and have used before, rather
than those from agencies. “Most reputable clinics choose
their own donors.” [Other provider #5]
Fig. 1 Issues concerning egg donor agencies
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Nonetheless, partly because finding good egg donors
can be hard, other clinics may both recruit donors on
their own, and use those from agencies.
I’m a nurse and have run the donor egg program at
my clinic for eight years. We recruit our own donors,
and have agency donors, too. The most difficult issues
are the recruitment of good donors, and the times
when recipients don’t get pregnant. [Other provider #7]
The fact that agencies generally offer much more
information about egg donors, often publicly online, can
pose challenges though for oocyte recipients and the
future children. Offspring created using purchased eggs
might eventually want to find their biological mother
using publicly available online data and information.
More knowledge about donors can decrease anonymity,
and create and shape expectations that children will
receive these donors’ desired traits, raising expectations
for the child.
Patients might come across the donor on the street. It’s
complicated. And there’s a limit in choosing. If patients
see the adult picture, it might distance them from the
child as they see their child growing.” [Other provider #5]
Yet questions emerge of whether these choices, based
on physical traits (e.g., height and blonde hair and blue
eyes), and educational institutions (e.g., Ivy League) and
attainment may at a certain point begin to raise
concerns about possible eugenics.
The quality of agencies varies
Agencies also range widely in quality, and some may be
better than others – in how well they evaluate, screen
and prepare potential donors. In part, as a result,
providers differ in their views of agencies.
A few providers had good experiences with agencies
with which they have worked, establishing on-going
relationships.
I haven’t worked with that many agencies. I’ve liked
the ones I know, that the clinic uses. Recently, we
used an agency and it turned out that the egg donor
didn’t produce good eggs that could be fertilized. We
would never have predicted it. The agency said it’s only
happened to them once. [Other provider-patient #10]
Yet other providers have also experienced this problem
of donors not ultimately producing sufficient usable
eggs, despite the agency having suggested otherwise,
suggesting that this problem may be more widespread
than this interviewee suspects..
Many clinicians had more mixed or negative views
and experiences concerning agencies. Agencies may, for
instance, list as donors women who have characteristics
that appeal to potential recipients, but turn out to be
unavailable.
Providers also often felt that egg donor agencies did
not always adequately screen donors. Clinicians thus
frequently conducted their own assessments of all
potential donors, including those from agencies.
Several clinics evaluate donors very carefully – much
more so than do agencies. We have a strict program
for our donors. We test donors a lot. One agency said
I reject donors that have donated elsewhere. We send
our donors’ profiles to a geneticist, and do extensive
psychological testing. We regulate it ourselves. [Other
provider #7]
Clinics may thus screen far more vigorously than do
agencies.
Agencies may also not fully inform, educate and
prepare prospective donors regarding the process, and
the risks involved. Financial profit may motivate certain
agencies, lowering their standards regarding which
donors they accept, and how well they assess these women.
A lot of these egg donors are not being vetted
properly. It’s big money. With the egg donor
agencies, anybody can sign up on-line. There’s
minimal screening. People can lie. Donors come
in, and are surprised at the depth of my questions
and the amount of detail. And I’m only asking
them standard questions! They’ll say they did a
psychological test on-line, which is really
unethical, because a psychological test is supposed
to be monitored. They’ll say, “Well, I met with
somebody.” Or: “I’ve met with someone in the
hallway for 10 minute,” or “The medical doctor
met with me and said ‘everything’s going to be
fine.’” But the doctor didn’t check whether the
donor understood what she would be undergoing.
Then they met with another psychologist or a
social worker, and it was much briefer. Or there
was nobody. Or they went to the clinic, and
signed up. Who does quality control? With egg
donor agencies, any female of the right age could
sign up on-line. Basically if somebody applies, the
agency will send a packet for them to fill out.
They may send them to be evaluated by someone,
have them do an abbreviated on-line psychological
test. It’s not hard to be put “on the books” as a
potential donor. They get often flown to a
different clinic, and by then, potential parents are
invested in them. [Other provider #5]
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Problems surface because agencies do not fully or
adequately probe potential donors’ personal or family
medical histories. Clinicians then have questions that
they come to probe further.
I see things on evaluations from the agencies that lead
me to question donors more. On one egg donor
evaluation, everything looked great. The father had
been dead for a number of years. “What did he die
of?” “He was murdered.” Given that information, I
would want to get a good idea about what happened.
[Other provider-patient #10]
Potential harms to donors
Practices of agencies could also potentially harm donors,
who come either to learn about medical problems about
which they were unaware, or they may face threats to
confidentiality. Since agency screening may be minimal
and/or superficial, some potential donors may suddenly
learn for the first time, from a clinic, that they are in fact
unsuitable, and/or have, or are at risk of, serious genetic
problems. These potential donors then confront unex-
pected stress.
Most patients go by the donor’s looks or education –
mostly looks – but I’ve turned down likeable,
attractive donors, saying: “We’re here to rule out
passing certain mutations to recipients. There are a
number of reasons why I may not think it’s a good
idea for you to proceed. This is not personal. It
doesn’t mean I don’t like you, or that you’re not nice.
But there are guidelines.” [Other provider #5]
Yet these donors had anticipated gaining financially, not
learning about their own genetic risks or diseases. Agencies
often do not inform donors about these potential pitfalls.
They get screened, and find out they have a genetic
problem that’s going to affect their own future! And
they’re not chosen as a donor, and don’t get paid!
Nobody says, “Here, go to this nice mental health
professional, and process how you just found out
you’ve got this problem.” They should go talk to
someone, but won’t. That’s a bum rap. Donors are
looking for money, but can’t say that. They have to
say they’re altruistic, or they won’t get chosen. But
most are financially motivated. [Other provider #5]
Stigmatized, personal medical information about donors
may also get spread, threatening their confidentiality.
We’ve seen confidentiality problems. By HIPAA [the
Health Insurance Portability and Accountability Act],
we can only give information we find about the donor
to the donor, not the agency. But the agency then
calls the donor, and asks her a lot of questions. She’s
young and vulnerable and gives answers. The agency
then gives out that medical information, which could
be venereal disease testing, genetic testing, or drug
testing, to the recipients. That is probably not illegal,
because the agencies are not professionals – so they
don’t have to behave according to professional
guidelines or ethics. So they give information about
one person to another. [Physician #14]
U.S. laws bar health care providers and institutions, but
not egg donor agencies, from sharing personal information
about potential donors with others – including clinicians,
prospective parents and the public-at-large. Many agencies
provide photos and extensive information about egg donors
on websites, and/or send copies to prospective egg
recipients and clinicians.
Policy implications: overseeing agencies?
Concerns arose that agencies do not always adhere to, or
help promote, key parts of current guidelines – for in-
stance, not monitoring the maximum number of times a
woman can sell her eggs.
Guidelines aren’t necessarily being followed. The
guidelines say egg donors are only supposed to donate
six times, but a lot of agencies don’t respect that,
despite what it can do to women’s bodies. I’ve read on
the Internet and seen books by donors who say they
don’t tell agencies what they’ve been through. Nor do
the agencies necessarily ask. Major medical centers ask.
For-profit agencies may not. [Other provider-patient #9]
Many – but not all – providers may then exercise
heightened caution regarding potential donors’ numbers
of prior donations, probing for this information very
thoroughly. Yet other clinicians may simply accept the
agency’s report of the potential donor’s past history
regarding donations and other relevant behaviors.
It’s difficult to be 100 % sure that donors from
agencies keep track of the number of cycles. One
donor told me she’s never donated before. But she
knew too much about egg donation. She seemed to
think that the injections were gonna be a piece of
cake. I said, “Something’s not adding up here. What’s
going on?” She then told me she “had a cycle done
elsewhere,” and “wasn’t happy” with the way they
treated her. [Other provider #7]
Consequently, this provider now regularly checks
records of women who have donated elsewhere. But
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agencies do not always agree to give this crucial
information.
I check records every time I can get them – 60 % of the
time – because we use a lot of agency donors. When an
agency donor has done a previous cycle, I’ve gotten the
records in every case – except when the program won’t
release them to me. [Other provider #7]
At times, questions arise of whether egg donor agencies
should be overseen in some way, though doing so presents
challenges, obstacles and questions.
I would find some way to put the brokers and
agencies out of business. But you’d have to figure out
how to do that. I would put this aspect of medical
care into the hands of medical professionals, and out
of the hands of business people! [Physician #14]
The fact that egg agencies are involved with medical
procedures, but are not operated by medical professionals
can thus create problems.
Discussion
These data, the first to explore how ART providers view
and interact with egg donor agencies, raise several crit-
ical ethical issues. Clinicians often use agencies in order
to have more supply of eggs, and give patients more
choices; but agencies appear to vary widely in quality –
in how well they screen, inform and prepare donors for
the process. These companies may not assess or record
well how many times donors have previously provided
oocytes; and may not agree to share the relevant records
with clinics. Potential donors may end up learning about
medical problems about which they were unaware; yet
agencies and clinics generally do not provide care or
resources for further assessment or treatment, and such
potential donors may then confront unforeseen stresses.
Moreover, dissemination of donors’ personal data can
potentially threaten confidentiality.
This study builds on earlier research on studies of
agency advertisements and staff [19, 29, 30], but offers
for the first time data on provider perspectives and expe-
riences, suggesting additional ethical concerns regarding
many agencies – problems that have not been previously
reported – e.g., regarding the quality of screenings and
potential harms. These data suggest that not all agencies
are deficient, but many appear to be so. While some
clinicians may screen potential donors with added care,
other providers may not do so as well. Agencies increase
choices in numbers of egg donor traits, but may also
foster both misunderstandings about genetics, and
eugenic-like notions that may have harmful, longer-term
effects. These data also pose concerns, post-Kamakahi,
about undue inducement, with more women seeking
to sell their eggs through agencies for increasing
amounts of money, without fully considering the vari-
ous potential risks involved. In particular, many agen-
cies and clinics may not fully or appropriately inform,
educate or vet these young women. Egg donation is
more invasive than sperm donation, requiring
medications and needles, and thus involves more risk
(i.e., of Ovarian Hyperstimulation Syndrome [31]),
heightening concerns.
These data are from the US, but have important impli-
cations for other countries. Though many European
countries ban payment to egg donors beyond limited
compensation for time and expenses [32], citizens of
these and other countries may travel to the US to pur-
chase eggs; and in upcoming years, agencies may well be
established in additional countries across the globe that
may regulate the egg market little, if at all.
These findings have critical implications for future
practice, education, guidelines and research. Specifically,
these findings suggest that further guidelines, oversight,
or regulation may be beneficial. Though currently, agen-
cies may register with ASRM, 41.2 % do not do so, and
most of those that do so in fact violate ASRM guidelines
[33, 34]. ASRM could potentially require that agencies
register with the organization in order to work with its
members; and more strongly emphasize needs to adhere
fully to ASRM guidelines. Professional medical organiza-
tions could also more strongly recommend that agencies
fully inform potential donors about the benefits and
risks of donation – including the possibility that poten-
tial donors may learn about medical problems for which
treatment will not be provided by ART clinics. It is cru-
cial that egg donors provide appropriate informed con-
sent, which necessitates that they fully understand the
potential risks involved. Unfortunately, it appears that
donors at many agencies may not always do so. Clinics
themselves should also provide this information; but as
Kahneman and Tversky [35] have described, an “anchor-
ing heuristic” exists, whereby initial information that
individuals receive “anchors” or establishes a mental
framework that shapes how later information is weighed,
molding subsequent decisions [36]. Hence, informing
potential donors initially about all relevant risks and in-
formation is vital.
ASRM or other policymakers could also mandate that
agencies adequately screen potential donors, specifying
components of appropriate screening; carefully track the
total number of times donors have contributed oocytes
and provide this information to clinics, if requested; and
only list as available those donors who are indeed avail-
able. Such recommendations could help ensure that the
highest possible ethical standards are followed. Moreover,
agencies could report key data to SART or Centers for
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Disease Control (CDC) annually, as ART clinics do – e.g.,
the number of women who donate each year, the number
of times each woman has donated, and any complications
that arise, to allow for enhanced transparency and help in
monitoring and overseeing this growing industry. The
CDC could require that all agencies provide such data.
Given the potential limitations of the current model of
self-regulation, the present findings suggest needs to
consider stronger professional guidelines or possible
governmental regulations to establish, require and en-
force higher standards for agencies to follow, regarding
advertising to potential donors and recipients, arranging
for appropriate informed consent concerning risks and
benefits involved, and for quality control. Given that the
system of self-regulation has had limited effectiveness,
with current ASRM guidelines routinely ignored by
many egg donor agencies, and that no legal redress
appears to exist for failing to comply with the current
guidelines, much stronger enforcement of guidelines or
governmental regulations at least need to be considered
as options. The federal government (through the CDC
or Federal Drug Administration) or states (through de-
partments of health) could require that all agencies
register, report data, and become certified. State depart-
ments of education and professional licensing could
require that egg donor agency owners and/or key em-
ployees become licensed, which could require formal legal
agreements to adhere to the highest possible standards.
Providers should recognize the wide differences that exist
in the quality of agencies; and should proceed with care.
Education of patients and potential egg providers is also
vital, to highlight needs for caution regarding the practices
of many – though not all – agencies. Appropriate informed
consent should be obtained from potential egg donors, in-
cluding the fact that they may learn about mutations or
medical problems about which they were unaware, but for
which they will not receive treatment as part of this
process. Enhancing understanding among the public-at-
large about what egg donation involves may also be helpful.
These data suggest both needs for future research and
a research agenda, to investigate further, using larger
samples, how often and which clinics use agencies;
which characteristics of agencies lead providers to use
these companies; what kinds of screening agencies con-
duct of potential donors, and how it can be improved;
how frequently physicians reject potential donors and
why (e.g., how often potential donors are found to have
serious mutations or other medical problems); and how
well egg donors understand the processes and potential
risks involved. These data also underscore, more
broadly, how qualitative data can illuminate the “on the
ground” experiences of providers and patients, revealing
ethical challenges, complexities, and nuances they
confront.
This study has several potential limitations. The sample
size is sufficient for qualitative research designed to eluci-
date the issues and themes that emerge; however, future
studies using larger samples are needed to analyze statisti-
cally several aspects of these issues (e.g., which clinics do
vs. do not use agencies). Though it is potentially conceiv-
able that providers with certain attitudes may have been
more likely to participate for some reason, the inter-
viewees here demonstrated a full range of attitudes. None-
theless, future studies can explore these issues with larger
samples. However, physicians and other clinicians are very
busy, and increasingly difficult to recruit for surveys, as in-
dicated by response rates of surveys of providers declining
significantly over time [37, 38]. Recruiting larger numbers
of them can pose challenges, no doubt accounting in part
for the lack of any prior studies on these critical questions,
and making the present data of added value. Arguably,
these data also have a certain face validity, illuminating
challenges that arise.
Conclusions
These data, the first to examine providers’ views and inter-
actions regarding egg donor agencies, suggest wide varia-
tions in quality and use of agencies, and have critical
implications for practice, policy, education and research.
Given the potential limitations of the current model of self-
regulation of agencies, the present data suggest needs to
consider stronger professional guidelines or possible gov-
ernmental regulations to establish, require and enforce
higher standards for agencies to follow, regarding advertis-
ing to potential donors and recipients, arranging for appro-
priate informed consent concerning risks and benefits
involved, and for quality control. Appropriate informed
consent should be obtained from potential egg donors,
including the fact that they may learn about mutations or
medical problems about which they were unaware, but for
which they will not receive treatment as part of this process.
Enhancing understanding among the public-at-large about
what egg donation entails involves may also be helpful.
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